Amarantus Subsidiary Cutanogen Corporation Announces Issuance of US Patent 14/299,480 Covering ESS, Pigmented ESS and Gene Therapy-Modified ESS
23 janv. 2018 09h59 HE
|
Amarantus Bioscience Holdings, Inc.
Patent Issuance Opens Potential to genetically modify cells used to produce ESS Peer-Reviewed publication demonstrates improved donor cosmetic skin color matching of melanocytes-implanted ESS vs....